Trial Profile
Randomized Double-Blind Comparison of an Alpha-1 Proteinase Inhibitor (Kamada API) With a Currently Marketed API Product in Individuals With Alpha-1 Antitrypsin Deficiency
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 09 Nov 2015
Price :
$35
*
At a glance
- Drugs Alpha 1-antitrypsin (Primary)
- Indications Alpha 1-antitrypsin deficiency
- Focus Therapeutic Use
- Sponsors Kamada
- 06 May 2015 According to Kamada media release, based on the results from this trial the company is planning to submit a Marketing Authorization Application with the European Medicines Agency for Conditional Approval of inhaled AAT therapy to treat AATD patients.
- 06 May 2015 According to Kamada media release, results will be presented at the upcoming American Thoracic Society (ATS) 2015 International Conference.
- 24 Dec 2014 New trial record